Scientists Resurrect Ancient Cannabis Enzymes to Unlock New Medical Cannabinoids

In a discovery that rewrites the origin story of your favorite plant, researchers at Wageningen University & Research in the Netherlands have done something that sounds more like science fiction than biochemistry: they brought back to life enzymes from an ancient ancestor of cannabis that walked (or rather, grew) the earth more than 25 million years ago.

Published in the journal Plant Biotechnology Journal in early 2026, the landmark study provides the first direct experimental evidence showing how cannabis evolved its remarkable ability to produce cannabinoids — the chemical compounds including THC, CBD, and CBC that have made the plant so medically and culturally significant. More than an evolutionary curiosity, the work points toward an entirely new class of cannabinoid medicines that could be produced more efficiently than ever before.

How Do You Resurrect a 25-Million-Year-Old Enzyme?

The answer lies in a technique called ancestral sequence reconstruction (ASR). While scientists cannot extract biological material from ancient cannabis plants (no cannabis equivalent of amber-preserved dinosaur DNA exists), they can work backward from the genetics of modern plants to infer what ancient genes looked like.

By comparing the genomes of present-day cannabis with related plants — including hops (Humulus lupulus), its closest living relative, and other members of the Cannabaceae family — the Wageningen team traced the evolutionary history of the enzyme family responsible for making cannabinoids. Using sophisticated computational models, they reconstructed the likely DNA sequences of cannabinoid-producing enzymes as they existed before cannabis and hops diverged into separate species more than 25 million years ago.

Those reconstructed sequences were then synthesized in the lab and expressed in yeast cells, effectively "turning on" enzymes that had not existed in any living organism for tens of millions of years.

What the Ancient Enzymes Revealed

The findings are striking. The research revealed a clear evolutionary progression:

The earliest ancestral enzyme produced none of the three major cannabinoids — not THC, CBD, or CBC. The biochemical machinery for making these compounds hadn't evolved yet.

A later ancestral version functioned as a generalist, synthesizing all three cannabinoids simultaneously. This "jack of all trades" enzyme is estimated to have existed roughly in the period before cannabis and hops fully separated as species.

Modern cannabis enzymes are specialists. Today's cannabis has three distinct enzymes — THCA synthase, CBDA synthase, and CBCA synthase — each responsible for producing one cannabinoid and one only. Over millions of years of evolution, the original generalist enzyme was duplicated through gene events, and each copy gradually "focused" on a single molecule.

The team's work, led by researchers in the Wageningen plant biotechnology group and published collaboratively with colleagues across Europe, provides the first experimental proof of this evolutionary story. Previous understanding was largely theoretical.

Why This Matters for Medicine

The medical implications are significant, and they hinge on a surprising property of the ancient enzymes: they are often easier to work with in the lab than their modern descendants.

Present-day cannabinoid synthase enzymes are notoriously finicky when produced in microbial systems like yeast or bacteria. They fold incorrectly, produce low yields, and require specialized conditions — all of which makes bioengineered cannabinoid production expensive and inefficient. Pharmaceutical companies interested in producing pure, consistent cannabinoids at scale have struggled with this limitation.

The resurrected ancient enzymes don't share these difficulties. Because they evolved before the intense specialization that made modern cannabis enzymes so precise (and so fragile), the ancestral versions are more robust, more stable, and easier to express in yeast cells at high yields.

One ancient enzyme reconstructed in the study was found to be particularly effective at producing CBC (cannabichromene), a cannabinoid that has attracted growing research interest for its potential anti-inflammatory, antidepressant, and neuroprotective properties. Unlike THC and CBD, CBC has no efficient natural enzyme in modern cannabis dedicated exclusively to high-yield production — making the ancient generalist enzyme a potentially valuable biotechnology tool.

The Bigger Picture: Cannabinoids Without Cannabis

This research fits into a growing scientific movement toward what researchers call "cell factory" production of cannabinoids — making these compounds in microbes rather than in plants.

The advantages of microbial production are significant: year-round production unaffected by climate, no agricultural land required, highly consistent purity, ability to produce rare cannabinoids in quantities impossible to extract from plant material, and potential to create novel cannabinoid derivatives that don't exist in nature.

Companies like Demetrix and others have already been pursuing yeast-based cannabinoid production, though yields and costs have remained challenging. The Wageningen team's ancestral enzyme discovery could provide exactly the kind of enzymatic shortcut needed to make microbial cannabinoid manufacturing commercially viable.

Beyond the cannabinoids already known, the ability to "replay" enzyme evolution opens the door to designing novel cannabinoid variants — molecules that sit between the modern specialized compounds and the ancient generalist's broad output. These synthetic cannabinoids could have unique pharmacological profiles not found in any strain of cannabis currently growing anywhere on earth.

What This Means for the Cannabis Industry

For most consumers, the direct impact of this research is still years away. But the pathway it opens is clear:

Cannabis-derived medicines — already a growing segment following the reclassification of FDA-approved marijuana products to Schedule III in April 2026 — may increasingly be produced not from plant-grown cannabis, but from engineered microbes using enzymes designed from evolutionary blueprints. This could mean more consistent pharmaceutical-grade cannabinoids, lower production costs for medicines, and the eventual arrival of entirely new cannabinoid therapeutics targeting conditions that current THC and CBD formulations can't effectively address.

For researchers and the pharmaceutical industry, the Wageningen study is a fundamental advance. It demonstrates that the evolutionary history of cannabis isn't just scientifically interesting — it's practically useful.

Key Takeaways

• Wageningen University researchers used ancestral sequence reconstruction to synthesize and test cannabis enzymes from 25+ million years ago, before cannabis and hops diverged.
• The ancient enzymes evolved from a generalist (producing THC, CBD, and CBC simultaneously) to today's three specialized enzymes through gene duplication events.
• Ancient enzymes are more robust and easier to express in yeast, making them valuable tools for bioengineered cannabinoid production.
• One resurrected enzyme excels at producing CBC, a cannabinoid with significant but underexplored medical potential.
• The research opens a path toward microbial "cell factory" production of cannabinoids — including novel compounds not found in any living cannabis plant.

Stay informed on the latest cannabis science, strain reviews, and dispensary news at Budpedia.